Keytruda is the cancer drug you cannot afford to ignore. Keytruda has proved to be complete success story across multiple indications. However, a major part of the drug's valuation today is based on its success in non small cell lung cancer segment. And riding high on this success is Merck (NYSE:MRK). Today, for majority of investors, Merck is Keytruda and vice versa. In 2016, the drug reported revenues close to $1.4 billion, and entered the league of blockbuster therapies.
The fortunes of Merck and Keytruda have become tightly intertwined. And with patents protecting the drug till year 2028, I believe this blockbuster therapy, Keytruda and its foray in lung cancer indication, is definitely a very solid reason you should consider investing in Merck in 2017.
